We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

7 hedge funds and large institutions have $243K invested in Pasithea Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,351% more capital inflows, than outflows

Capital inflows: $243K | Capital outflows: $1.8K

17% more funds holding

Funds holding: 6 → 7 (+1)

5.2% more ownership

Funds ownership: 0.87% → 6.08% (+5.2%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.77K
2
Bank of America
Bank of America
North Carolina
-$35

KTTA Hedge Fund Activity: Q4 2024 in Review

7 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2024, worth a combined $243K — up 398% from $48.9K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new KTTA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $216K. The largest seller was Morgan Stanley, cutting an estimated $1.77K.

  • 7 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $243K of Pasithea Therapeutics stock for Q4 2024, up 398% quarter-over-quarter.
  • 1 fund opened new Pasithea Therapeutics positions in Q4 2024 and 0 closed out, a net change of +1 holder.
  • The largest Pasithea Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $216K added.
  • The largest Pasithea Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $1.77K sold.

Based on aggregated 13F filings for Q4 2024.